Health and Healthcare
Is the Actavis $21 Billion Bond Sale Just the First?
Published:
Last Updated:
With virtually everyone expecting the Federal Reserve to raise interest rates later this year, other companies with golden credit ratings may also turn to the bond markets.
The Actavis bond issue was heavily oversubscribed, with orders for $90 billion, even though the yield on a 10-year note was just 1.75% above the 10-year Treasury rate. Given the demand, yields may be even lower. At the bell on Monday afternoon, the 10-year Treasury yield was 2.1%.
The bonds vary in maturity from 18 months to 30 years, carry an investment-grade rating and are seen as a very good investment with Treasury rates so low. The bonds are expected to be delivered in 10 tranches
Actavis is not the only big borrower making news. Exxon Mobil Corp. (NYSE: XOM) is also believed to be about to offer $7 billion in bonds, its largest ever debt deal. Exxon’s AAA credit rating means that the oil giant may end up paying less than 1% over the comparable U.S. Treasury rate.
Actavis shares traded down about 0.2% just before noon on Tuesday, at $296.86 in a 52-week range of $184.71 to $297.50. The high was posted Monday.
ALSO READ: 4 High-Yield Health Care Real Estate Investment Trusts to Buy Now
Ever wanted an extra set of eyes on an investment you’re considering? Now you can speak with up to 3 financial experts in your area for FREE. By simply
clicking here you can begin to match with financial professionals who can help guide you through the financial decisions you’re making. And the best part? The first conversation with them is free.
Click here to match with up to 3 financial pros who would be excited to help you make financial decisions.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.